Shares of DocGo Inc. (NASDAQ:DCGO - Get Free Report) have been assigned an average rating of "Hold" from the six research firms that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $2.3750.
Several equities analysts have commented on DCGO shares. Wall Street Zen upgraded shares of DocGo from a "sell" rating to a "hold" rating in a research note on Saturday, May 16th. Cantor Fitzgerald reiterated an "overweight" rating on shares of DocGo in a report on Monday, May 11th. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of DocGo in a research note on Thursday, June 18th.
View Our Latest Stock Analysis on DocGo
Hedge Funds Weigh In On DocGo
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Neuberger Berman Group LLC acquired a new stake in DocGo in the fourth quarter valued at approximately $29,000. Cerity Partners LLC purchased a new stake in shares of DocGo during the 2nd quarter worth $37,000. Public Employees Retirement System of Ohio purchased a new stake in shares of DocGo during the 4th quarter worth $40,000. Engineers Gate Manager LP acquired a new position in shares of DocGo during the second quarter worth $52,000. Finally, Jain Global LLC acquired a new position in shares of DocGo during the fourth quarter worth $70,000. 56.44% of the stock is owned by institutional investors and hedge funds.
DocGo Price Performance
Shares of DocGo stock opened at $0.62 on Friday. The business has a 50-day moving average of $0.59 and a 200 day moving average of $0.65. DocGo has a 12 month low of $0.45 and a 12 month high of $1.78. The stock has a market capitalization of $61.72 million, a price-to-earnings ratio of -0.33 and a beta of 0.99.
DocGo (NASDAQ:DCGO - Get Free Report) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.10). The business had revenue of $75.55 million for the quarter, compared to analysts' expectations of $72.48 million. DocGo had a negative return on equity of 44.09% and a negative net margin of 62.23%. Equities research analysts anticipate that DocGo will post -0.12 earnings per share for the current year.
DocGo Company Profile
(
Get Free Report)
DocGo, Inc is a U.S.-based integrated healthcare company that delivers on-demand and mobile healthcare services. The company’s business model centers on deploying customized medical clinics paired with a digital care platform to bring primary and acute care directly to patients. Through a combination of telemedicine and over-the-road medical units, DocGo addresses routine medical exams, chronic disease management, occupational health screenings, specialist consultations and urgent care interventions.
In addition to its mobile clinic fleet, DocGo’s digital platform offers 24/7 virtual care, facilitating remote consultations via video, phone or secure messaging.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider DocGo, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DocGo wasn't on the list.
While DocGo currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.